SLAB Stock Analysis: Silicon Laboratories | NASDAQ
Semiconductors | NASDAQ, USA | Market Cap: 7.306m USD | 12M Return: 68.2% | US8269191024 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 53.0M
Qual. Beats: -1
Rev. Trend: 21.9%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Silicon Laboratories (NASDAQ: SLAB) is a fabless semiconductor company founded in 1996 and headquartered in Austin, Texas. It designs mixed-signal analog-intensive chips used across a broad range of industrial IoT, commercial IoT, smart home, and connected health applications, including smart metering, industrial automation, smart lighting, asset tracking, wireless microcontrollers, and medical instrumentation. The company sells through a direct sales force along with independent sales representatives and distributors, serving customers in the United States, China, Taiwan, and other international markets.
The fabless model allows SLAB to avoid the capital costs of operating fabrication facilities, outsourcing production to third-party foundries. Mixed-signal semiconductors integrate analog and digital functions on a single chip, which is increasingly important for IoT endpoints that must sense, process, and wirelessly transmit data with low power consumption. SLAB is classified in the Information Technology sector under the Semiconductors sub-industry and is positioned in the mid-cap range with a market capitalization of roughly $7.2 billion.
- Industrial IoT chip demand accelerates amid automation capex
- China revenue exposure pressures overall sales growth
- Gross margins pressured by foundry costs and analog competition
| Net Income: -39.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.00 > 0.02 and ΔFCF/TA -6.58 > 1.0 |
| NWC/Revenue: 63.92% < 20% (prev 70.69%; Δ -6.77% < -1%) |
| CFO/TA 0.03 > 3% & CFO 33.1m > Net Income -39.1m |
| Net Debt (-373.3m) to EBITDA (10.2m): -36.49 < 3 |
| Current Ratio: 5.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (33.2m) vs 12m ago 1.60% < -2% |
| Gross Margin: 59.90% > 18% (prev 54.95%; Δ 4.95% > 0.5%) |
| Asset Turnover: 69.19% > 50% (prev 57.59%; Δ 11.60% > 0%) |
| Interest Coverage Ratio: -34.10 > 6 (EBIT TTM -31.5m / Interest Expense TTM 923k) |
| A: 0.44 (Total Current Assets 671.2m - Total Current Liabilities 124.1m) / Total Assets 1.25b |
| B: 0.73 (Retained Earnings 910.3m / Total Assets 1.25b) |
| C: -0.03 (EBIT TTM -31.5m / Avg Total Assets 1.24b) |
| D: 6.92 (Book Value of Equity 1.09b / Total Liabilities 158.3m) |
| Altman-Z'' = 12.33 = AAA |
| DSRI: 1.16 (Receivables 79.8m/56.5m, Revenue 855.9m/703.2m) |
| GMI: 0.92 (GM 54.95% / 59.90%) |
| AQI: 0.93 (AQ_t 0.36 / AQ_t-1 0.39) |
| SGI: 1.22 (Revenue 855.9m / 703.2m) |
| TATA: -0.06 (NI -39.1m - CFO 33.1m) / TA 1.25b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of September 02, 2026, the stock is trading at USD 219.12 with a total of 254,767 shares traded. Over the past week, the price has changed by +0.34%, over one month by +0.51%, over three months by +0.57% and over the past year by +68.18%.
Current recommended Stop Loss: 217.80 (which is 0.6% or 1.3 ATR below the current price).
Silicon Laboratories has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold SLAB.
- StrongBuy: 3
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 222.9 | 1.7% |
P/E Forward = 75.7576
P/S = 8.5357
P/B = 6.6718
P/EG = 3.1179
Revenue TTM = 855.9m USD
EBIT TTM = -31.5m USD
EBITDA TTM = 10.2m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 24.0m USD (Leases only: 24.0m)
Net Debt = -373.3m USD (calculated: Debt 24.0m - CCE 397.2m)
Enterprise Value = 6.93b USD (7.31b + Debt 24.0m - CCE 397.2m)
Interest Coverage Ratio = -34.10 (Ebit TTM -31.5m / Interest Expense TTM 923k)
EV/FCF = -1000.0x (Enterprise Value 6.93b / FCF TTM -5.43m)
FCF Yield = -0.08% (FCF TTM -5.43m / Enterprise Value 6.93b)
FCF Margin = -0.63% (FCF TTM -5.43m / Revenue TTM 855.9m)
Net Margin = -4.57% (Net Income TTM -39.1m / Revenue TTM 855.9m)
Gross Margin = 59.90% ((Revenue TTM 855.9m - Cost of Revenue TTM 343.2m) / Revenue TTM)
Gross Margin QoQ = 61.65% (prev 56.65%)
Tobins Q-Ratio = 5.53 (Enterprise Value 6.93b / Total Assets 1.25b)
Interest Expense / Debt = 3.85% (Interest Expense 923k / Debt 24.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -24.9m (EBIT -31.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.41 (Total Current Assets 671.2m / Total Current Liabilities 124.1m)
Debt / Equity = 0.02 (Debt 24.0m / totalStockholderEquity, last quarter 1.09b)
Debt / EBITDA = -36.49 (Net Debt -373.3m / EBITDA 10.2m)
Debt / FCF = 68.72 (negative FCF - burning cash) (Net Debt -373.3m / FCF TTM -5.43m)
Total Stockholder Equity = 1.09b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.16% (Net Income -39.1m / Total Assets 1.25b)
RoE = -3.59% (Net Income TTM -39.1m / Total Stockholder Equity 1.09b)
RoCE = -2.79% (EBIT -31.5m / Capital Employed (Total Assets 1.25b - Current Liab 124.1m))
RoIC = -2.29% (negative operating profit) (NOPAT -24.9m / Invested Capital 1.09b)
WACC = 10.96% (E(7.31b)/V(7.33b) * Re(10.99%) + D(24.0m)/V(7.33b) * Rd(3.85%) * (1-Tc(0.21)))
Discount Rate = 10.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 99.17 | Cagr: 1.79%
[DCF] Fair Price = unknown (Cash Flow -5.43m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: 21.92 | Revenue CAGR: 4.78% | SUE: 0.26 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.69 | Chg30d=+0.36% | Revisions=+25% | Analysts=8
EPS current Year (2026-12-31): EPS=2.92 | Chg30d=+5.81% | Revisions=+25% | GrowthEPS=+217.6% | GrowthRev=+18.1%
EPS next Year (2027-12-31): EPS=4.36 | Chg30d=+5.12% | Revisions=+25% | GrowthEPS=+49.2% | GrowthRev=+16.5%
[Analyst] Revisions Ratio: +50% (up=3, down=0)